Whether deuterated colexitinib (decavatinib) is suitable for long-term oral use and safety analysis

Deucravacitinib is a selective TYK2 inhibitor mainly used to treat moderate to severe plaque psoriasis and some autoimmune diseases. Its oral administration method is convenient, and its mechanism of drug action controls skin lesions by regulating immune signaling pathways and reducing the production of inflammatory mediators. Because of its high target selectivity and little impact on other signaling pathways such as JAK1/JAK2, it is more suitable for long-term maintenance treatment than traditional broad-spectrum immunosuppressants and is expected to reduce systemic side effects.

In terms of efficacy, long-term oral use of decavatinib shows good disease control capabilities. Clinical trials have shown that after several months of continuous medication, the patient's rash improved significantly, itching and scaly symptoms were relieved, and the compliance rate of PASI 75 and PASI 90 was maintained, and the recurrence rate was low. This shows that the drug can not only take effect quickly, but also maintain its efficacy during long-term use, providing patients with a stable improvement in their quality of life.

In terms of safety, long-term oral administration of decavatinib is generally well tolerated. The most common adverse reactions include upper respiratory tract infection, headache, mild diarrhea and mild changes in blood lipids. Most are mild to moderate and can be relieved by themselves or managed through symptomatic treatment. Compared with traditional JAK inhibitors, the incidence of serious infections, blood clots and hematological abnormalities is lower. However, during long-term use, it is still necessary to regularly monitor blood routine, liver and kidney function, and blood lipids to detect potential risks in a timely manner.

Overall, deuterated colexitinib is suitable for long-term oral maintenance treatment, especially for patients with moderate to severe psoriasis and autoimmune diseases. Its high selectivity, oral convenience and good safety make it a reliable choice for sustainable medication. Under standardized monitoring and physician guidance, patients can benefit in the long term while minimizing the risk of serious adverse reactions.

Reference materials:https://www.nlm.nih.gov/